{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:29:45Z","timestamp":1778819385530,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This current investigation was aimed to generate signals for adverse events (AEs) of darunavir-containing agents by data mining using the US Food and Drug Administration Adverse Event Reporting System (FAERS). All AE reports for darunavir, darunavir\/ritonavir, or darunavir\/cobicistat between July 2006 and December 2019 were identified. The reporting Odds Ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) were used to detect the risk signals. A suspicious signal was generated only if the results of the three algorithms were all positive. A total of 10,756 reports were identified commonly observed in hepatobiliary, endocrine, cardiovascular, musculoskeletal, gastrointestinal, metabolic, and nutrition system. 40 suspicious signals were generated, and therein 20 signals were not included in the label. Severe high signals (i.e. progressive extraocular muscle paralysis, acute pancreatitis, exfoliative dermatitis, acquired lipodystrophy and mitochondrial toxicity) were identified. In pregnant women, umbilical cord abnormality, fetal growth restriction, low birth weight, stillbirth, premature rupture of membranes, premature birth and spontaneous abortion showed positive signals. Darunavir and its boosted agents induced AEs in various organs\/tissues, and were shown to be possibly associated with multiple adverse pregnant conditions. This study highlighted some novel and severe AEs of darunavir which need to be monitored prospectively.<\/jats:p>","DOI":"10.1038\/s41598-021-91549-w","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T10:03:10Z","timestamp":1623664990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiaojiang","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanglin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuntao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"91549_CR1","unstructured":"Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017 (World Health Organization, 2017)."},{"key":"91549_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"MS Saag","year":"2018","unstructured":"Saag, M. S. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA 320, 379\u2013396. https:\/\/doi.org\/10.1001\/jama.2018.8431 (2018).","journal-title":"JAMA"},{"key":"91549_CR3","unstructured":"Global HIV & AIDS statistics\u20142020 fact sheet https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"91549_CR4","first-page":"63","volume":"10","author":"E Vispo","year":"2008","unstructured":"Vispo, E. Warning on hepatotoxicity of darunavir. AIDS Rev. 10, 63 (2008).","journal-title":"AIDS Rev."},{"key":"91549_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jaad.2010.01.061","volume":"63","author":"CE Introcaso","year":"2010","unstructured":"Introcaso, C. E., Hines, J. M. & Kovarik, C. L. Cutaneous toxicities of antiretroviral therapy for HIV. J. Am. Acad. Dermatol. 63, 549\u2013561. https:\/\/doi.org\/10.1016\/j.jaad.2010.01.061 (2010).","journal-title":"J. Am. Acad. Dermatol."},{"key":"91549_CR6","unstructured":"US Department of Health and Human Services (HHS) Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/PerinatalGL.pdf. Updated December 24, 2019. Accessed 2 Jan 2020."},{"key":"91549_CR7","unstructured":"Antiretroviral pregnancy registry steering committee. The Antiretroviral pregnancy registry:interim report-1 January 1989 through 31 July 2015. http:\/\/www.apregistry.com\/forms\/interim_report.pdf (2015)."},{"key":"91549_CR8","unstructured":"LiverTox: clinical and research information on drug induced liver injury. Darunavir. [Updated 2017 Sep 1] (National Institute of Diabetes and Digestive and Kidney Diseases, 2012)."},{"key":"91549_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1177\/0956462419826723","volume":"30","author":"N Yancheva","year":"2019","unstructured":"Yancheva, N. & Tzonev, R. A case of late presentation of darunavir-related cholestatic hepatitis. Int. J. STD AIDS 30, 620\u2013622. https:\/\/doi.org\/10.1177\/0956462419826723 (2019).","journal-title":"Int. J. STD AIDS"},{"key":"91549_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/hiv.12784","volume":"20","author":"JL Casado","year":"2019","unstructured":"Casado, J. L. et al. Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. HIV Med. 20, 648\u2013656. https:\/\/doi.org\/10.1111\/hiv.12784 (2019).","journal-title":"HIV Med."},{"key":"91549_CR11","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/ndt\/gfr376","volume":"27","author":"N Bige","year":"2012","unstructured":"Bige, N. et al. Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. Nephrol. Dial Transplant. 27, 1114\u20131121. https:\/\/doi.org\/10.1093\/ndt\/gfr376 (2012).","journal-title":"Nephrol. Dial Transplant."},{"key":"91549_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1086\/381783","volume":"189","author":"E Fontas","year":"2004","unstructured":"Fontas, E. et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?. J. Infect. Dis. 189, 1056\u20131074. https:\/\/doi.org\/10.1086\/381783 (2004).","journal-title":"J. Infect. Dis."},{"key":"91549_CR13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","volume":"369","author":"B Clotet","year":"2007","unstructured":"Clotet, B. et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 369, 1169\u20131178. https:\/\/doi.org\/10.1016\/S0140-6736(07)60497-8 (2007).","journal-title":"Lancet"},{"key":"91549_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","volume":"17","author":"PW Mallon","year":"2003","unstructured":"Mallon, P. W., Miller, J., Cooper, D. A. & Carr, A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17, 971\u2013979. https:\/\/doi.org\/10.1097\/00002030-200305020-00005 (2003).","journal-title":"AIDS"},{"key":"91549_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00002030-200101260-00013","volume":"15","author":"KV Heath","year":"2001","unstructured":"Heath, K. V. et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV\/AIDS treatment database. AIDS 15, 231\u2013239. https:\/\/doi.org\/10.1097\/00002030-200101260-00013 (2001).","journal-title":"AIDS"},{"key":"91549_CR16","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","volume":"19","author":"MP Dube","year":"2005","unstructured":"Dube, M. P. et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19, 1807\u20131818. https:\/\/doi.org\/10.1097\/01.aids.0000183629.20041.bb (2005).","journal-title":"AIDS"},{"key":"91549_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1086\/507333","volume":"43","author":"DA Wohl","year":"2006","unstructured":"Wohl, D. A. et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin. Infect. Dis. 43, 645\u2013653. https:\/\/doi.org\/10.1086\/507333 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"91549_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","volume":"357","author":"E Martinez","year":"2001","unstructured":"Martinez, E. et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 357, 592\u2013598. https:\/\/doi.org\/10.1016\/S0140-6736(00)04056-3 (2001).","journal-title":"Lancet"},{"key":"91549_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1468-1293.2012.01004.x","volume":"13","author":"MA Valantin","year":"2012","unstructured":"Valantin, M. A. et al. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir\/ritonavir monotherapy versus darunavir\/ritonavir plus nucleoside reverse transcriptase inhibitors: The MONOI-ANRS136 substudy. HIV Med. 13, 505\u2013515. https:\/\/doi.org\/10.1111\/j.1468-1293.2012.01004.x (2012).","journal-title":"HIV Med."},{"key":"91549_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/NEJMra041811","volume":"352","author":"S Grinspoon","year":"2005","unstructured":"Grinspoon, S. & Carr, A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352, 48\u201362. https:\/\/doi.org\/10.1056\/NEJMra041811 (2005).","journal-title":"N. Engl. J. Med."},{"key":"91549_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-201X.2004.01383.x","volume":"183","author":"A Rudich","year":"2005","unstructured":"Rudich, A., Ben-Romano, R., Etzion, S. & Bashan, N. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol. Scand. 183, 75\u201388. https:\/\/doi.org\/10.1111\/j.1365-201X.2004.01383.x (2005).","journal-title":"Acta Physiol. Scand."},{"key":"91549_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","volume":"173","author":"MS Freiberg","year":"2013","unstructured":"Freiberg, M. S. et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern. Med. 173, 614\u2013622. https:\/\/doi.org\/10.1001\/jamainternmed.2013.3728 (2013).","journal-title":"JAMA Intern. Med."},{"key":"91549_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/QAD.0b013e32835b2ef1","volume":"27","author":"A Monforte","year":"2013","unstructured":"Monforte, A. et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 27, 407\u2013415. https:\/\/doi.org\/10.1097\/QAD.0b013e32835b2ef1 (2013).","journal-title":"AIDS"},{"key":"91549_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5527\/wjn.v5.i1.33","volume":"5","author":"CG Musso","year":"2016","unstructured":"Musso, C. G., Belloso, W. H. & Glassock, R. J. Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients. World J. Nephrol. 5, 33\u201342. https:\/\/doi.org\/10.5527\/wjn.v5.i1.33 (2016).","journal-title":"World J. Nephrol."},{"key":"91549_CR25","unstructured":"Prezista (darunavir) (prescribing information) (Janssen Therapeutics, 2019)."},{"key":"91549_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-226912","author":"N Makaram","year":"2018","unstructured":"Makaram, N., Russell, C. D., Roberts, S. B., Stevens, J. & Macpherson, G. Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction between cobicistat and intrabursal triamcinolone. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2018-226912 (2018).","journal-title":"BMJ Case Rep."},{"key":"91549_CR27","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cid\/ciu701","volume":"59","author":"J Schouten","year":"2014","unstructured":"Schouten, J. et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: The AGEhIV cohort study. Clin. Infect. Dis. 59, 1787\u20131797. https:\/\/doi.org\/10.1093\/cid\/ciu701 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"91549_CR28","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/02770903.2010.485666","volume":"47","author":"E Kedem","year":"2010","unstructured":"Kedem, E., Shahar, E., Hassoun, G. & Pollack, S. Iatrogenic Cushing\u2019s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J. Asthma 47, 830\u2013831. https:\/\/doi.org\/10.3109\/02770903.2010.485666 (2010).","journal-title":"J. Asthma"},{"key":"91549_CR29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/INF.0000000000001534","volume":"36","author":"PG Rainsbury","year":"2017","unstructured":"Rainsbury, P. G. et al. Ritonavir and topical ocular corticosteroid induced Cushing\u2019s syndrome in an adolescent with HIV-1 infection. Pediatr. Infect. Dis. J. 36, 502\u2013503. https:\/\/doi.org\/10.1097\/INF.0000000000001534 (2017).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"91549_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00002030-200401230-00002","volume":"18","author":"A Cossarizza","year":"2004","unstructured":"Cossarizza, A. & Moyle, G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18, 137\u2013151. https:\/\/doi.org\/10.1097\/00002030-200401230-00002 (2004).","journal-title":"AIDS"},{"key":"91549_CR31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0149-2918(00)80064-8","volume":"22","author":"G Moyle","year":"2000","unstructured":"Moyle, G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin. Ther. 22, 911\u2013936. https:\/\/doi.org\/10.1016\/S0149-2918(00)80064-8 (2000) (discussion 898).","journal-title":"Clin. Ther."},{"key":"91549_CR32","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.survophthal.2019.11.001","volume":"65","author":"E Kisilevsky","year":"2020","unstructured":"Kisilevsky, E., Freund, P. & Margolin, E. Mitochondrial disorders and the eye. Surv. Ophthalmol. 65, 294\u2013311. https:\/\/doi.org\/10.1016\/j.survophthal.2019.11.001 (2020).","journal-title":"Surv. Ophthalmol."},{"key":"91549_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11910-016-0652-7","volume":"16","author":"C McClelland","year":"2016","unstructured":"McClelland, C., Manousakis, G. & Lee, M. S. Progressive external ophthalmoplegia. Curr. Neurol. Neurosci. Rep. 16, 53. https:\/\/doi.org\/10.1007\/s11910-016-0652-7 (2016).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"91549_CR34","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/00002030-199814000-00004","volume":"12","author":"K Brinkman","year":"1998","unstructured":"Brinkman, K., ter Hofstede, H. J., Burger, D. M., Smeitink, J. A. & Koopmans, P. P. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 12, 1735\u20131744. https:\/\/doi.org\/10.1097\/00002030-199814000-00004 (1998).","journal-title":"AIDS"},{"key":"91549_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jaad.2010.01.061","volume":"63","author":"CE Introcaso","year":"2010","unstructured":"Introcaso, C. E., Hines, J. M. & Kovarik, C. L. Cutaneous toxicities of antiretroviral therapy for HIV: Part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J. Am. Acad. Dermatol. 63, 549\u2013561. https:\/\/doi.org\/10.1016\/j.jaad.2010.01.061 (2010) (quiz 561\u2013542).","journal-title":"J. Am. Acad. Dermatol."},{"key":"91549_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jiac.2014.01.004","volume":"20","author":"T Nishijima","year":"2014","unstructured":"Nishijima, T. et al. Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting. J. Infect. Chemother. 20, 285\u2013287. https:\/\/doi.org\/10.1016\/j.jiac.2014.01.004 (2014).","journal-title":"J. Infect. Chemother."},{"key":"91549_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/11593240-000000000-00000","volume":"13","author":"N Mittmann","year":"2012","unstructured":"Mittmann, N. et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: An observational, retrospective case series study. Am. J. Clin. Dermatol. 13, 49\u201354. https:\/\/doi.org\/10.2165\/11593240-000000000-00000 (2012).","journal-title":"Am. J. Clin. Dermatol."},{"key":"91549_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00015550310002611","volume":"83","author":"A Rotunda","year":"2003","unstructured":"Rotunda, A., Hirsch, R. J., Scheinfeld, N. & Weinberg, J. M. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm. Venereol. 83, 1\u20139. https:\/\/doi.org\/10.1080\/00015550310002611 (2003).","journal-title":"Acta Derm. Venereol."},{"key":"91549_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","volume":"46","author":"JM Molina","year":"2007","unstructured":"Molina, J. M. et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J. Acquir. Immune Defic. Syndr. 46, 24\u201331. https:\/\/doi.org\/10.1097\/QAI.0b013e3181359cfb (2007).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"91549_CR40","first-page":"1938","volume":"90","author":"CM Wilcox","year":"1995","unstructured":"Wilcox, C. M., Straub, R. F. & Clark, W. S. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am. J. Gastroenterol. 90, 1938\u20131941 (1995).","journal-title":"Am. J. Gastroenterol."},{"key":"91549_CR41","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","volume":"5","author":"C Orkin","year":"2018","unstructured":"Orkin, C. et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): A phase 3, randomised, non-inferiority trial. Lancet HIV 5, e23\u2013e34. https:\/\/doi.org\/10.1016\/S2352-3018(17)30179-0 (2018).","journal-title":"Lancet HIV"},{"key":"91549_CR42","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1086\/323783","volume":"33","author":"ME Coghlan","year":"2001","unstructured":"Coghlan, M. E. et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: A report of 12 cases. Clin. Infect. Dis. 33, 1914\u20131921. https:\/\/doi.org\/10.1086\/323783 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"91549_CR43","unstructured":"Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/perinatalgl.pdf (Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, 2016)."},{"key":"91549_CR44","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/17512433.2017.1390428","volume":"10","author":"R Pope Jr","year":"2017","unstructured":"Pope, R. Jr. & Kashuba, A. Darunavir for use in pregnant women with HIV. Expert Rev. Clin. Pharmacol. 10, 1317\u20131327. https:\/\/doi.org\/10.1080\/17512433.2017.1390428 (2017).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"91549_CR45","unstructured":"Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2016. http:\/\/www.APRegistry.com. Accessed 21 July 2016 (Registry Coordinating Center, 2016)."},{"key":"91549_CR46","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S2352-3018(19)30340-6","volume":"7","author":"PL Williams","year":"2020","unstructured":"Williams, P. L. et al. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): A prospective cohort study. Lancet HIV 7, e49\u2013e58. https:\/\/doi.org\/10.1016\/S2352-3018(19)30340-6 (2020).","journal-title":"Lancet HIV"},{"key":"91549_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12978-016-0149-5","volume":"13","author":"YM Mesfin","year":"2016","unstructured":"Mesfin, Y. M., Kibret, K. T. & Taye, A. Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysis. Reprod. Health 13, 30. https:\/\/doi.org\/10.1186\/s12978-016-0149-5 (2016).","journal-title":"Reprod. Health"},{"key":"91549_CR48","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/infdis\/jir307","volume":"204","author":"KM Powis","year":"2011","unstructured":"Powis, K. M. et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J. Infect. Dis. 204, 506\u2013514. https:\/\/doi.org\/10.1093\/infdis\/jir307 (2011).","journal-title":"J. Infect. Dis."},{"key":"91549_CR49","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/cid\/cis198","volume":"54","author":"J Sibiude","year":"2012","unstructured":"Sibiude, J. et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: Role of the ritonavir boost?. Clin. Infect. Dis. 54, 1348\u20131360. https:\/\/doi.org\/10.1093\/cid\/cis198 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"91549_CR50","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int. J. Med .Sci. 10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med .Sci."},{"key":"91549_CR51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pds.1746","volume":"18","author":"E Poluzzi","year":"2009","unstructured":"Poluzzi, E., Raschi, E., Moretti, U. & De Ponti, F. Drug-induced torsades de pointes: Data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol. Drug Saf. 18, 512\u2013518. https:\/\/doi.org\/10.1002\/pds.1746 (2009).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"91549_CR52","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/sim.3586","volume":"28","author":"I Ahmed","year":"2009","unstructured":"Ahmed, I. et al. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting. Stat. Med. 28, 1774\u20131792. https:\/\/doi.org\/10.1002\/sim.3586 (2009).","journal-title":"Stat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91549-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91549-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91549-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:36:36Z","timestamp":1670060196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91549-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91549"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91549-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12438"}}